Piramal Pharma Limited Announces Consolidated Results for Q1FY25

Key Highlights for Q1FY25  Key Highlights for Q1FY25  Nandini Piramal, Chairperson, Piramal Pharma Limited,said, " We have had a good start to the financial year with a steady all-round performance. We delivered a healthy revenue growth accompanied by over 170bps YoY expansion in EBIDTA margin driven by favorable revenue mix and cost optimization initiatives. Our CDMO business continues to witness sustained order inflows, especially for on-patent commercial manufacturing. We are also...

MUMBAI, India, 26/07/2024 (informazione.news - comunicati stampa - salute e benessere)

said, "

Piramal Pharma Limited will be hosting a conference call for investors / analysts on

The dial-in details for the call are as under:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. In October 2020 , PPL received a 20% strategic growth investment from the Carlyle Group. 

For more information, visit: Piramal Pharma | LinkedIn

Logo: https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q1fy25-302207455.html